Myanmar Health Sciences Research Journal

Archives   2015

Myanmar   Health   Sciences   Research   Journal

Volume   27,  Number   2

TITLE:   Efficacy and Safety of Combination Therapy of Peginterferon Alfa-2a and Ribavirin among Chronic Hepatitis C Patients in Yangon
AUTHOR:   Than Sitt, Aye Thandar Aung, Myat Myat Mu & Sandar Hnin Swe
SOURCE:   Myanmar Health Sciences Research Journal. 2015; 27(2): 155-162
ABSTRACT:   The aim was to determine efficacy and safety of Peg IFN alfa-2a plus ribavirin (RBV) in Myanmar patients with chronic hepatitis C in Yangon. A total 362 Patients, 175 males (48.34%) and 187 females (51.66%) aged 47.12(±SD, 11.60) years from 2008 to 2012, were treated with weekly Peg IFN alfa-2a (90 or 135 or 180 µg) plus daily oral ribavirin 800 to 1200 mg/day for 24 or 48 weeks depending on genotype and extended 4 or 12 weeks depending on viral response. HCV genotype 1(G1) was 102(28.18%), G3 in 178(49.17%), G6 in 66(18.23%), and G2 in 4(1.10%) patients. Genotype was found to be indeterminate in 12(3.31%). Efficacy was conducted by plasma HCV RNA measurements at the end of week 4, 12, 24, and at the end of treatment and 24 weeks after the treatment. Dropout was 65(17.95%), breakthrough was 5(1.68%) and non-responder was 6(2.02%). Among 286 completed therapy, 195(68.18%) patients were tested SVR (sustained viral response i.e., viral absence 24 weeks after completion of treatment) and 91(31.81%) failed to test SVR. Relapse was found in 28(14.36%). SVR was 167(85.64%) including 39(81.25%) of G1, 94(85.45%) of G3, 28(90.32%) of G6, 2(100.00%) of G2, 4(100.00%) of Genotype indeterminate among the patients. Serious adverse effects such as death or life threatening conditions were not noted. The therapy was effective (SVR≥80%) and well-tolerated. Though this retrospective analytic study is effective in enthusiastic patients eager to complete the treatment, this therapy will be replaced by newer, shorter and simpler oral therapy with less side-effects. Keywords: PEG/RBV dual therapy for chronic HCV, Myanmar
SUBJECT HEADINGS:   PEG/RBV dual therapy for chronic HCV, Myanmar

Back to Articles

Vision : Achieving a healthier nation through application of research findings          Mission Statement : To Develop and promote solutions to the major health problems of Myanmar